Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
3.82 SEK | -3.41% | -3.17% | +23.62% |
08/04 | Oncozenge AB Appoints Paolo Bossi as Member of the Advisory Board | CI |
04/04 | OncoZenge Announces Read-Out of Positive Stability Data for BupiZenge | CI |
Sales 2024 * | - | Sales 2025 * | - | Capitalization | 46.33M 503M 3.87B |
---|---|---|---|---|---|
Net income 2024 * | -8M -86.9M -668M | Net income 2025 * | - | EV / Sales 2024 * | - |
Net cash position 2024 * | 3M 32.59M 251M | Net cash position 2025 * | 3M 32.59M 251M | EV / Sales 2025 * | - |
P/E ratio 2024 * |
-5.82
x | P/E ratio 2025 * |
-
| Employees | 2 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 33.97% |
1 day | -3.41% | ||
1 week | -3.17% | ||
Current month | +2.69% | ||
1 month | -6.83% | ||
3 months | +0.53% | ||
6 months | +44.70% | ||
Current year | +23.62% |
Managers | Title | Age | Since |
---|---|---|---|
Stian Kildal
CEO | Chief Executive Officer | - | 13/23/13 |
Michael Owens
DFI | Director of Finance/CFO | 68 | 12/23/12 |
Markus Jerling
CTO | Chief Tech/Sci/R&D Officer | 72 | 01/21/01 |
Members of the board | Title | Age | Since |
---|---|---|---|
Christoph Nowak
BRD | Director/Board Member | 38 | 09/23/09 |
Date | Price | Change | Volume |
---|---|---|---|
13/24/13 | 3.82 | -3.41% | 7 853 |
10/24/10 | 3.955 | +2.20% | 16,453 |
08/24/08 | 3.87 | +0.78% | 25,628 |
07/24/07 | 3.84 | -2.66% | 13,987 |
06/24/06 | 3.945 | +2.73% | 48,293 |
Delayed Quote Nasdaq Stockholm, May 13, 2024 at 02:12 pm IST
More quotesEPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+23.62% | 4.27M | |
+30.38% | 684B | |
+29.81% | 568B | |
-4.36% | 361B | |
+19.30% | 329B | |
+3.73% | 284B | |
+16.26% | 240B | |
+9.00% | 208B | |
-7.57% | 200B | |
+7.68% | 166B |
- Stock Market
- Equities
- ONCOZ Stock